Top 3 Coronavirus Stocks To Buy Now

Don’t let the ongoing vaccine rollout make you think coronavirus stocks are an old hat. Until the global caseload drops to manageable levels, we will still need new vaccines, many diagnostic tests and as many therapeutic drugs as we can get our hands on COVID-19 patients. and prevent people from contracting the disease.

The trap? Competition for market share is intensifying. So picking a winning coronavirus stock now is a little harder than it was in 2020. Being the first to get a product approved for sale clearly doesn’t mean it will capture the entire market. Investors should look to focus on companies that will make products that are significantly better than the competition.

1. Johnson & Johnson

While Johnson & johnson (NYSE: JNJ) is still working on its coronavirus vaccine candidate, it has a big advantage that vaccines by Pfizer (NYSE: PFE) and Modern (NASDAQ: ARNM) do not: it only takes one dose to generate immunity. This means that it doesn’t need to manufacture as many to meet demand. This has the added benefit of making the logistics of administering vaccines much easier, as people will only have to come to a clinic once and clinics will need to procure fewer syringes and related products. than with competing vaccines. But the candidate will have to pass its final phase of clinical trials and get regulatory approval before investors can count on profits.

J & J’s vaccine will have another competitive advantage: better storage and transport characteristics. While Pfizer’s vaccine requires transport and storage in ultra-cold freezers, J&J can be stored at standard medical refrigerator temperatures for up to 90 days. In such a refrigerator, Pfizer’s vaccine can only stay for five days before spoiling. This means that J&J’s candidate is easier to deploy for smaller clinics, which is likely to be a major factor in their purchasing decision. The caveat here is that everything I have said assumes the candidate is just as effective as the others in the market. If it is not as effective in preventing serious illness, it will be a major disadvantage.

2. Abbott Laboratories

Abbott Laboratories (NYSE: ABT) isn’t working on a vaccine, but its diagnostic tests make it a lucrative coronavirus stockpile. Due to its strong leadership in testing throughout the pandemic, Abbott’s US-based diagnostics sales revenue increased 61.4% in the third quarter from a year ago. In total, the company has eight different tests that are approved for sale, covering every coronavirus diagnostic window imaginable. Its latest rapid test product is designed for home use and provides consumers with cost-effective results without the use of complicated and expensive lab equipment.

Given the high demand for testing, Abbott should continue to thrive, especially if it continues to innovate in consumer testing solutions. In particular, the company’s NAVICA smartphone app for tracking test results is likely to be a major value driver for consumers looking for test products in a growing field of competitors. Expect Abbott to continue to develop and publish more sophisticated coronavirus diagnostic tests and to focus on digital solutions such as NAVICA that add benefits such as traceability and third-party verification of diagnostic results.

3. Co-diagnosis

Unlike Abbott or J&J, Co-diagnosis (NASDAQ: CODX) is a small cap stock that grows like wildfire. This year, the company sold more than 10 million of its coronavirus molecular diagnostic tests, earning it $ 21.8 million in the third quarter alone. But Co-Diagnostics is just getting started, and management expects its performance to be even better in the next quarter.

Investors should expect two catalysts for the share price after the next earnings report. First, its new home saliva-based coronavirus diagnostic test was recently launched. Second, its joint venture in India began selling the company’s diagnostic test at the end of November, which could further boost its revenue. Next year will also be an exciting one for investors. Co-Diagnostics is working on a new molecular test intended for use in research settings to detect coronaviral mutations. He is also working on a new line of multiplexed tests using research that detect influenza A, influenza B and coronavirus from the same sample. Stay tuned for the next corporate earnings report to see how much new revenue these projects generate, and invest accordingly.